Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan

F. Raspagliesi, S. Kusamura, J. C. Campos Torres, G. A. de Souza, A. Ditto, F. Zanaboni, R. Younan, D. Baratti, L. Mariani, B. Laterza, M. Deraco

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: We report the effects of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of advanced/recurrent epithelial ovarian cancer (EOC) on survival, morbidity and mortality. Patients: Forty EOC patients were studied. Median age was 52.5 years (range: 30-68) and median follow-up 26.1 months (range: 0.3-117.6). Most patients presented advanced disease (stage III/IV). Previous systemic chemotherapy included cisplatin-based, taxol-based or taxol/platinum containing regimens. Results: After the CRS, 33 patients presented no macroscopic residual disease. Five-year overall survival was 15%; the mean overall and progression-free survivals were 41.4 and 23.9 months, respectively. The morbidity, toxicity and mortality rates were 5%, 15% and 0%, respectively. Conclusion: Our results suggest that CRS + IPHP merits further evaluation by a formal prospective trial.

Original languageEnglish
Pages (from-to)671-675
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume32
Issue number6
DOIs
Publication statusPublished - Aug 2006

Keywords

  • Advanced ovarian cancer
  • Locoregional therapy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan'. Together they form a unique fingerprint.

Cite this